Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 24, 2019

Second Genome doses first patient in Phase II NASH drug trial

Second Genome has dosed the first patient in a Phase II clinical trial assessing SGM-1019 for the treatment of nonalcoholic steatohepatitis (NASH), a subtype of nonalcoholic fatty liver disease (NAFLD).

Second Genome has dosed the first patient in a Phase II clinical trial assessing SGM-1019 for the treatment of nonalcoholic steatohepatitis (NASH), a subtype of nonalcoholic fatty liver disease (NAFLD).

SGM-1019 is an oral, small molecule inhibitor of the P2X7 receptor that can activate inflammasome, and mediate inflammation and fibrosis.

The company intends to enrol 100 patients at sites across the US for the randomised, double-blind, placebo-controlled trial.

The trial aims to investigate the preliminary safety, tolerability, pharmacokinetics, and efficacy of twice-daily dosing of oral SGM-1019 at two different dose levels.

“SGM-1019 has the potential to provide a much-needed treatment option for the growing number of patients with NASH.”

It is expected to provide top-line data in the first half of next year.

The trial’s principal investigator Stephen Harrison said: “There are no approved therapies for NASH at this time, and, while there are many in development, SGM-1019 is directed at the inflammation underlying this condition.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“We know that inhibiting P2X7 results in significant reduction in inflammation and fibrosis in preclinical models of disease and look forward to seeing the data from this study.

“SGM-1019 has the potential to provide a much-needed treatment option for the growing number of patients with NASH.”

The National Institute of Diabetes and Digestive and Kidney Diseases suggests around 3% to 12% of the US population is affected by NASH.

The disease commonly attacks obese people or those who have other metabolic conditions, including type 2 diabetes or elevated lipids.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU